AB-255 / Angiocrine - LARVOL DELTA

[VIRTUAL] ANTIBODY FREE, MASS SPECTROMETRIC PROCEDURE FOR THE DETERMINATION OF AΒ40 AND AΒ42 IN HUMAN PLASMA (CTAD 2020) - "Clinical performance of ABtestMS was tested by ROC analysis to discriminate Aβ-PET+ve versus Aβ-PET-ve individuals in a pilot study using a subset of 36 samples from the AB255 study... ABtestMS allows the robust and reliable quantification of Aβ42/Aβ40 ratio in plasma without requiring preliminary immunoprecipitation nor enzymatic digestion of the sample. The Aβ42/Aβ40 ratio in plasma as determined by ABtestMS, could be useful for the identification of cognitive normal people with cerebral β-amyloid preclinical Alzheimer’s pathologic change."

Alzheimer's Disease • CNS Disorders • CSF Aβ42

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. (PubMed, Alzheimers Res Ther) - "Plasma TP42/40 ratio showed a relevant and significant potential as a screening tool to identify brain Aβ positivity in preclinical and prodromal stages of Alzheimer's disease."

Journal • Alzheimer's Disease • Amyloidosis • CNS Disorders • Cognitive Disorders